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(1 / (placebo fracture risk – treatment fracture risk) for vertebral (VF), non-vertebral 
(NVF) and hip fractures (HF) were derived as a function of fracture risks and compli-
ance rates associated with each therapy. Both drug costs and efﬁcacies were adjusted 
to compliance rates. Relative risks and placebo incidences of each fracture type 
were obtained from the clinical trials, meta-analyses from NICE reviews, and costs 
were gathered from local price database. Annual compliance rates were taken from 
the literature (Willemijn, Cur Med Res Opin 2008;24:3217–22). RESULTS: Com-
pared to each oral bisphosphonate (OB), ZOL generated the lowest clinical NNTs 
for all fracture sites. Under conservative compliant patient rate of 50% for weekly 
and 75% for monthly OBs, cost of treatment to prevent one fracture in 3 years 
was a30,625 (VF) and a160,400 (HF) for ZOL; a76,800 (VF) and a272,900 (HF) 
for branded alendronate; a75,825a (VF) and a269,325a (HF) for generic alendronate; 
a170,250 (VF) and a783,400 (HF) for risedronate; and a65,725 (VF) for ibandronate. 
Sensitivity analyses were performed. CONCLUSIONS: In the Turkish setting, 
compared to all OBs once-yearly administered ZOL was dominantly the most 
cost-effective treatment regardless of fracture type upto a level of 90% compliance 
with oral therapies.
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OBJECTIVES: To evaluate the cost effectiveness of zoledronic acid 5 mg once yearly 
compared to generic alendronate in postmenopausal patients with osteoporosis. 
METHODS: A cost effectiveness model, based on the model used in the NICE apprais-
als of the cost effectiveness of osteoporosis treatments in postmenopausal women at 
increased risk of fracture, was adapted to the Danish setting. Lifetime costs and quality 
adjusted life years (QALYs) were calculated assuming ﬁve years of treatment. Relative 
risks of fracture protection were obtained from the HORIZON-PFT trial for zole-
dronic acid 5 mg, and from meta-analyses from NICE reviews for generic alendronate, 
assumed to be equal to branded alendronate. Compliance with zoledronic acid was 
assumed to be 100% (by deﬁnition of a once-yearly infusion) and sensitivity analyses 
were conducted for the compliance with generic alendronate, with decreased efﬁcacy 
extrapolated from the relationship between compliance and probability of fracture 
(Siris, 2006). Costs of fractures were taken from Danish cost studies and/or DRG cost 
lists and pharmacy costs of the medications were based on ofﬁcial list prices. Utilities 
were obtained from the literature. RESULTS: For patients 70 years old with a T-score 
of 2.5, zoledronic acid dominated generic alenronate when compliance with generic 
alendronate was 70% or lower. The dominating cost effectiveness of zoledronic acid 
over generic alendronate increased with decreased generic alendronate compliance, 
with incremental cost effectiveness ratios (ICERs) of between 5.077 DKK for 70% 
compliance and 48,202 DKK for 50% compliance. CONCLUSIONS: A single annual 
infusion of zoledronic acid 5 mg provides cost savings over daily generic alendronate, 
assuming a conservative real-life compliance of 70% for generic alendronate. There-
fore, despite the availability of cheaper generics, their poor compliance results in cost 
savings for a more expensive alternative with better compliance. Further data is needed 
to make conclusions on longer term implications.
PMS38
ECONOMIC ANALYSIS OF DABIGATRAN ETEXILATE FOR THE 
PRIMARY PREVENTION OF VENOUS THROMBOEMBOLISM 
FOLLOWING TOTAL HIP OR KNEE REPLACEMENT IN SPAIN
Gonzalez-Rojas N1, Vieta A2, Monreal M3, Wolowacz SE4
1Boehringer Ingelheim, Sant Cugat del Vallés, Barcelona, Spain, 2IMS Health, Barcelona, Spain, 
3Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain, 4RTI-Health Solutions, 
Manchester, UK
OBJECTIVES: Evaluate the cost-effectiveness of dabigatran etexilate compared with 
enoxaparin for the primary prophylaxis of venous thromboembolism (VTE) after total 
hip replacement (THR) or total knee replacement (TKR) in Spain. METHODS: A 
published cost-effectiveness model was adapted to the perspective of the Spanish 
National Health Service. Oral dabigatran etexilate 220 mg/day was compared with 
injectable enoxaparin 40 mg/day. The efﬁcacy and safety of the treatments was deter-
mined from two pivotal phase III studies comparing these interventions. The model 
combined a decision tree for the peri-operative period (acute phase, 10 weeks) with a 
Markov model for long-term events (chronic phase, 60 years). The treatment patterns, 
consumption of resources and costs were based on quantitative (databases, patient 
registries, ofﬁcial statistics) and qualitative (systematic literature review, expert 
surveys) data sources for Spain. Univariate deterministic and probabilistic sensitivity 
analyses were performed. RESULTS: The study results suggest that overall outcomes 
do not differ signiﬁcantly between dabigatran etexilate and enoxaparin. Mean Life 
years were 0.018 and 0.020 higher for dabigatran patients undergoing THR and TKR 
respectively; mean QALYs were 0.013 and 0.015 higher respectively. Mean overall 
costs were lower for dabigatran patients by a189 and a53 respectively. In the proba-
bilistic sensitivity analysis, dabigatran etexilate was dominant for most of the one 
thousand simulations in THR. The probability that dabigatran is cost-effective at a 
threshold of a30,000/QALY was 99% in THR and 87% in TKR. In the deterministic 
sensitivity analysis, dabigatran was dominant versus enoxaparin in all scenarios in 
both THR and TKR. CONCLUSIONS: From the viewpoint of the Spanish NHS, 
primary prophylaxis with dabigatran etexilate (220 mg/day orally) has a lower cost 
than enoxaparin (40 mg/day subcutaneously) after THR and TKR with a comparable 
efﬁcacy and safety proﬁle.
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OBJECTIVES: The management of moderate to severe rheumatoid arthritis includes 
the use of biologic agents. Modelling allows simulation of complex biologic treatment 
strategies after an insufﬁcient response (IR) to previous biologic agents. The objective 
is to assess the cost-effectiveness of various biologic treatment sequences over two 
years according to the Turkish health care system using a public payer perspective. 
METHODS: Six treatment strategies using three successive biologic agents [etanercept 
(ETA), adalimumab (ADA), inﬂiximab (INF), abatacept (ABA) or rituximab (RTX)], 
were modelled based on Turkish medical practice. Effectiveness was derived from 
published evidence as expected number of days in low disease activity state (LDAS). 
Biologic treatment was maintained for achieving LDAS or switched at each six months 
in case of IR. Total medical costs were estimated per level of disease activity over 6 
months. Extensive probabilistic sensitivity analysis was performed. RESULTS: Con-
sidering an IR to 1 anti-TNF agent, the sequence ETA-ABA-ADA was more efﬁcacious 
and cost-effective (102 days in LDAS; 496 TL per day in LDAS) over 2 years than 
the sequence ETA-RTX-ADA (82 days in LDAS; 554 TL per day in LDAS or 81 days 
in LDAS; 563 TL / day in LDAS based on RTX current reimbursement status). Con-
sidering an IR after 2 anti-TNF agents, the sequences ETA-ADA-ABA and ETA-INF-
ABA were more efﬁcacious and cost-effective (64 days in LDAS for both; 841 and 
826 TL / day in LDAS, respectively) over 2 years than a sequence of anti-TNF agents 
only (32 days in LDAS; 1480 TL per day in LDAS). CONCLUSIONS: These simula-
tions suggest that over two years of therapy, sequences including abatacept after an 
IR to one anti-TNF agent are more efﬁcacious and cost-effective vs. similar sequences 
including rituximab. Sequences including abatacept after an IR to 2 anti-TNF agents 
also appear more effective and cost-effective than similar sequences composed of anti-
TNF agents only.
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OBJECTIVES: Progressive Rheumatoid Arthritis (RA) usually requires different thera-
peutic options used sequentially in case of an insufﬁcient response (IR) to previous 
agents. As clinical trials comparing biologic treatment sequences are lacking, simula-
tion models inform on optimal treatment sequences and their cost-effectiveness. The 
objective was to assess the cost-effectiveness of different biologic treatment strategies 
based on levels of disease activity using the perspective of the German public payer. 
METHODS: A cost-effectiveness sequential model was developed based on RA treat-
ment goals, using DAS28 scores as dichotomous endpoints: remission/no remission or 
Low Disease Activity State (LDAS)/no LDAS. Costs were estimated using a re-analysis 
of the published ‘ Hannover costing study’. Advanced simulations were conducted to 
assess the cost-effectiveness over 2 years of four sequential biologic strategies com-
posed of anti-TNF agents, abatacept and rituximab, in patients with moderate to 
severe active RA and an IR to at least one anti-TNF agent. RESULTS: Medical costs 
for patients in LDAS, remission or in moderate to high disease activity were estimated 
at a3929 (SD  8566), a4853 (SD  13488) and a7017 per 6 months (SD  11813), 
respectively. Over 2 years, the sequence with abatacept after 1 anti-TNF agent 
appeared the most effective and cost-effective, vs. use after 2 anti-TNF agents (a633 
vs. a1067/day in LDAS and a1222 vs. a3592/day in remission), and vs a similar 
sequence using rituximab (a633 vs. a728/day in LDAS and a1222 vs. a1812/day in 
remission). The sequence using a 3rd anti-TNF agent was less effective and cost-effec-
tive than the same sequence using abatacept (a2000 vs. a1067/day in LDAS and a6623 
vs. a3592/day in remission). CONCLUSIONS: Achieving LDAS or remission is associ-
ated with lower medical costs than high disease activity states. The results suggest that 
in patients with an IR to at least one anti-TNF agent, biologic sequences including 
abatacept appear more efﬁcacious and cost-effective than similar sequences including 
rituximab or cycled anti TNF agents.
